Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings.
In addition to our world-class employees, our chief competitive advantage is our proprietary access to the high-resolution crystal structure of the 50S subunit of the ribosome, a molecule which is essential for the viability of all bacterial pathogens and the target of numerous valuable antibiotics.
